Abstract
ABSTRACTBACKGROUNDRTS,S is the first malaria vaccine recommended for implementation among young children at risk. However, vaccine efficacy is modest and short-lived. Antibodies play the major role in vaccine-induced immunity, but knowledge on the induction, decay, and determinants of antibody function is limited, especially among children. Antibodies that promote opsonic phagocytosis and other cellular functions appear to be important contributors to RTS,S immunity.METHODSWe studied a phase IIb trial of RTS,S/AS02 conducted young children in malaria endemic regions of Mozambique. We evaluated the induction of antibodies targeting the circumsporozoite protein (CSP, vaccine antigen) that interact with Fcγ-receptors (FcRγs) and promote phagocytosis (neutrophils, monocytes, THP-1 cells), antibody-dependent respiratory burst (ADRB) by neutrophils, and natural killer (NK) cell activity, as well as the temporal kinetics of responses over 5 years of follow-up (ClinicalTrials.gov registry number NCT00197041).RESULTSRTS,S vaccination induced CSP-specific IgG with FcγRIIa and FcγRIII binding activity and promoted phagocytosis by neutrophils, THP-1 monocytes, and primary human monocytes, neutrophil ADRB activity, and NK cell activation. Responses were highly heterogenous among children, and the magnitude of neutrophil phagocytosis by antibodies was relatively modest, which may reflect modest vaccine efficacy. Induction of functional antibodies was lower among children with higher malaria exposure. Functional antibodies largely declined within a year post-vaccination, consistent with the decline in vaccine efficacy over that time, and decay rates varied for different antibody parameters. Biostatistical modelling suggested IgG1 and IgG3 contribute in promoting FcγR binding and phagocytosis, and IgG targeting the NANP-repeat and C-terminal regions CSP were similarly important for functional activities.CONCLUSIONSResults provide new insights to understand the modest and time-limited efficacy of RTS,S in children, and the induction of antibody functional activities. Improving the induction and maintenance of antibodies that promote phagocytosis and cellular functions, and combating the negative effect of malaria exposure on vaccine responses are potential strategies for improving RTS,S efficacy and longevity.
Publisher
Cold Spring Harbor Laboratory
Reference55 articles.
1. World Health Organization: World Malaria Report 2021. Geneva, Switzerland: World Health Organization; 2021.
2. World Health Organization: Malaria vaccine: WHO position paper -January 2016 2016.
3. World Health Organization: Ghana, Kenya and Malawi to take part in WHO malaria vaccine pilot programme. 2017.
4. Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
5. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children